Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Change in Receivables (2021 - 2025)

Historic Change in Receivables for Core Scientific (CORZ) over the last 5 years, with Q1 2025 value amounting to -$6000.0.

  • Core Scientific's Change in Receivables fell 10566.04% to -$6000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was -$771000.0, marking a year-over-year decrease of 18254.82%. This contributed to the annual value of -$659000.0 for FY2024, which is 18591.92% down from last year.
  • Latest data reveals that Core Scientific reported Change in Receivables of -$6000.0 as of Q1 2025, which was down 10566.04% from -$5.2 million recorded in Q4 2024.
  • Over the past 5 years, Core Scientific's Change in Receivables peaked at $9.4 million during Q2 2021, and registered a low of -$9.4 million during Q3 2021.
  • Over the past 5 years, Core Scientific's median Change in Receivables value was $780000.0 (recorded in 2021), while the average stood at $904647.1.
  • Data for Core Scientific's Change in Receivables shows a peak YoY increase of 69133.33% (in 2024) and a maximum YoY decrease of 473425.93% (in 2024) over the last 5 years.
  • Over the past 5 years, Core Scientific's Change in Receivables (Quarter) stood at $780000.0 in 2021, then skyrocketed by 43.46% to $1.1 million in 2022, then plummeted by 109.65% to -$108000.0 in 2023, then plummeted by 4734.26% to -$5.2 million in 2024, then surged by 99.89% to -$6000.0 in 2025.
  • Its last three reported values are -$6000.0 in Q1 2025, -$5.2 million for Q4 2024, and $887000.0 during Q3 2024.